Welcome to our dedicated page for Bristol-Myers Squibb Co news (Ticker: BMY), a resource for investors and traders seeking the latest updates and insights on Bristol-Myers Squibb Co stock.
Bristol Myers Squibb (NYSE: BMY) generates frequent news across drug development, regulatory milestones, clinical data and corporate actions, reflecting its role as a global biopharmaceutical company focused on serious diseases. News coverage on this page centers on how the company’s cardiovascular, oncology, hematology, immunology and neuroscience programs progress from clinical trials to regulatory decisions and real-world use.
Recent updates have highlighted positive Phase 3 trial results for Camzyos (mavacamten) in adolescents with symptomatic obstructive hypertrophic cardiomyopathy in the SCOUT-HCM study, including statistically significant improvements in left ventricular outflow tract gradients and safety findings consistent with adult experience. Other headlines feature regulatory developments such as the U.S. Food and Drug Administration granting priority review to an Opdivo (nivolumab) plus chemotherapy combination for previously untreated advanced classical Hodgkin lymphoma, and the FDA’s approval of Breyanzi (lisocabtagene maraleucel; liso-cel) for adults with relapsed or refractory marginal zone lymphoma.
Investors and followers of BMY can also expect news on hematology research presented at major medical meetings, including data on investigational targeted protein degradation agents like golcadomide and BMS-986458, and long-term follow-up results for Breyanzi in large B-cell and follicular lymphomas. Corporate and financial items appear as well, such as dividend declarations, debt offerings, tender offers for outstanding notes, and presentations at healthcare investment conferences.
This news feed brings together company press releases, clinical trial readouts, regulatory updates, access and affordability agreements, and SEC-reported events. For users tracking BMY stock, it offers a single place to review how Bristol Myers Squibb’s pipeline, marketed products and capital markets activity evolve over time. Bookmark this page to quickly review new trial results, FDA decisions, access initiatives and financial disclosures related to Bristol Myers Squibb.
Bristol Myers Squibb (NYSE:BMY) released new data on COVID-19 vaccine responses in participants treated with Zeposia (ozanimod) in the ongoing Phase 3 DAYBREAK trial for relapsing multiple sclerosis. The study indicated a 100% seroconversion rate in participants receiving mRNA vaccines, while 62% for non-mRNA vaccine recipients. Results show higher antibody levels in mRNA vaccine recipients, suggesting patients on Zeposia may benefit from booster doses. Findings will be presented on June 28, 2022, at the European Academy of Neurology Congress in Vienna.
Bristol Myers Squibb (NYSE: BMY) announced the validation of its type II variation application by the European Medicines Agency for Breyanzi to treat specific lymphoma types in adults, enhancing its role as a second-line therapy. This follows promising results from the TRANSFORM Phase 3 study, showcasing Breyanzi's superiority over the standard care with significant improvements in event-free survival and safety. The EMA review marks a critical step in advancing treatment options for patients with relapsed or refractory large B-cell lymphoma.
Bristol Myers Squibb (NYSE: BMY) announced a quarterly dividend of $0.54 per share on its common stock, payable on August 1, 2022, to stockholders of record by July 1, 2022. Additionally, a $0.50 dividend per share will be distributed on its convertible preferred stock, payable on September 1, 2022, to stockholders of record by August 9, 2022. The company continues its commitment to delivering value to its shareholders through consistent dividend payments.
Bristol Myers Squibb (NYSE: BMY) has appointed Dr. Deepak L. Bhatt to its Board of Directors, effective June 14, 2022. Dr. Bhatt, an expert in cardiovascular medicine, will also serve on the Science & Technology Committee. With over 20 years of research experience, he aims to enhance the company’s strategic development and innovation in treating serious diseases. This move expands the Board to 11 members, aligning with BMY's commitment to excellence in patient care and advancing its pipeline of medicines.
Bristol Myers Squibb (NYSE:BMY) is set to announce its second quarter 2022 financial results on July 27, 2022, at 8:00 a.m. ET. Company executives will host a conference call to review the results and answer questions from analysts and investors. A live webcast of the call will be accessible to the public via investor.bms.com. Replays of the call will be available starting at 11:30 a.m. EDT on the same day, continuing until August 10, 2022.
Bristol Myers Squibb (NYSE: BMY) will participate in a fireside chat at Goldman Sachs’ 43rd Annual Global Healthcare Conference in Rancho Palos Verdes, California, on Wednesday, June 15, 2022. Adam Lenkowsky, Senior VP and General Manager of U.S. Commercialization, will address questions starting at 9:20 a.m. PT/12:20 p.m. ET. Investors and the public can listen to a live webcast at investor.bms.com, where additional materials will also be available. An archived version will be accessible later that day.
Bristol Myers Squibb (NYSE: BMY) announced positive three-year follow-up results from the Phase 3 CheckMate -9LA trial for metastatic non-small cell lung cancer (mNSCLC). The trial demonstrated a significant improvement in overall survival (OS) with Opdivo and Yervoy, achieving a 27% survival rate compared to 19% for chemotherapy alone. Notably, results were favorable for patients with PD-L1 expression <1%. The safety profile remains consistent with previous findings. These findings underscore the potential of dual immunotherapy in addressing high unmet needs in mNSCLC.
Bristol Myers Squibb (BMY) reported five-year results from the Phase 3 CheckMate -227 trial, showing that the combination of Opdivo and Yervoy nearly doubled the overall survival rate at five years in patients with metastatic non-small cell lung cancer (mNSCLC) compared to chemotherapy. The five-year survival rate for patients with PD-L1 expression ≥1% was 24% for the immunotherapy combo, versus 14% for chemotherapy. In patients with PD-L1 expression <1%, survival rates were 19% vs. 7%. These results highlight the long-term efficacy and potential of Opdivo and Yervoy as first-line treatments.
Bristol Myers Squibb (NYSE: BMY) announced the withdrawal of its supplemental biologics license application for Reblozyl (luspatercept-aamt) aimed at treating anemia in adults with non-transfusion dependent beta thalassemia. The decision comes after the FDA raised concerns regarding the drug's benefit-risk profile based on data from the Phase 2 BEYOND trial. Despite this setback, the company continues to advance Reblozyl through a broad clinical development program.
Bristol Myers Squibb (NYSE:BMY) announced an all-cash tender offer to acquire Turning Point Therapeutics (NASDAQ:TPTX) for $76.00 per share, valuing the deal at approximately $4.1 billion. The acquisition includes repotrectinib, a promising next-generation ROS1/NTRK inhibitor, expected to launch in 2023 and enhance BMY's oncology portfolio. The deal is anticipated to be accretive to non-GAAP earnings per share starting in 2025. Both companies' boards unanimously approved the transaction, expected to close in Q3 2022, subject to customary conditions.
FAQ
What is the current stock price of Bristol-Myers Squibb Co (BMY)?
What is the market cap of Bristol-Myers Squibb Co (BMY)?
